Compare NMRA & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NMRA | BANX |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Trusts Except Educational Religious and Charitable |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.4M | 149.8M |
| IPO Year | 2023 | N/A |
| Metric | NMRA | BANX |
|---|---|---|
| Price | $2.05 | $22.05 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 970.4K | 23.4K |
| Earning Date | 11-06-2025 | 06-17-2025 |
| Dividend Yield | N/A | ★ 9.66% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | N/A | ★ $29,467,794.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.88 |
| Revenue Growth | N/A | ★ 2.73 |
| 52 Week Low | $0.61 | $17.99 |
| 52 Week High | $11.57 | $21.67 |
| Indicator | NMRA | BANX |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 58.72 |
| Support Level | $2.05 | $21.40 |
| Resistance Level | $2.36 | $22.50 |
| Average True Range (ATR) | 0.15 | 0.35 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 15.32 | 79.87 |
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.